|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||36.71 - 37.22|
|52 Week Range||30.90 - 37.22|
|PE Ratio (TTM)||22.98|
|Earnings Date||Jan 29, 2018 - Feb 2, 2018|
|Forward Dividend & Yield||1.28 (3.49%)|
|1y Target Est||38.24|
The FDA approves label expansion of Pfizer's (PFE) JAK inhibitor Xeljanz for two doses on an impressive data from two phase III studies.
Several presentations at the annual meeting of the American Society of Hematology grab headlines in the cancer space.
The Dow hammered out an early lead Friday, as investors looked to the possible release of a reconciled GOP tax reform package later in the morning.
Pfizer Inc. today announced the expiration and results of its previously announced offers to exchange and to repurchase any and all of its outstanding £1,500,000,000 6.500 per cent.
Shares of Pfizer appeared to be headed for a new high after the company announced that the FDA had approved its treatment for adult patients with active psoriatic arthritis.
U.S. drugmaker Pfizer Inc said on Thursday the U.S. Food and Drug Administration (FDA) approved two doses of its drug Xeljanz for treatment of a joint disease. Xeljanz was approved as a 5-mg dose taken twice daily and as an extended-release 11-mg dose taken once daily as a drug for patients with active psoriatic arthritis who have not responded to other treatments. Psoriatic arthritis, a form of arthritis that affects some people who have skin disease psoriasis, is characterized by symptoms such as joint pain, stiffness and swelling.
Pfizer Inc. announced today that the United States Food and Drug Administration has approved XELJANZ® 5 mg twice daily and XELJANZ® XR extended release 11 mg once daily for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs .
Everything's been going so well for Valeant Pharmaceuticals International (VRX). See, Valeant has been on quite a run. Since bottoming at $8.51 in April, Valeant's shares have rallied more than 130% as the beleaguered pharmaceutical company sold off assets, and paid down or extended its debt.
Pfizer’s Oncology segment accounts for less than 20% of the company’s value, according to our estimates. For many other major pharma companies, their oncology portfolios are larger contributors to their top lines, and Pfizer has been looking to capitalize on opportunities in the space.
The FDA approves Ixifi, Pfizer's (PFE) second biosimilar version of Johnson & Johnson's rheumatoid arthritis drug, Remicade. Ixifi receives the nod for all approved indications of Remicade.
Pfizer Inc. today announced the pricing terms of its previously announced offers to exchange and to repurchase any and all of its outstanding £1,500,000,000 6.500 per cent.
The 10 biggest antidepressant drug companies in 2017 are committed to providing the safest and most cost-effective solution for consumers suffering from mental diseases worldwide. According to Journal of the American Medical Association, one out of six Americans consumes psychiatric medicine and about 12% of these drugs are antidepressants. Depression is a state of mind, […]
Pfizer Inc. today announced the initiation of a Phase 3 program for its once-daily Janus kinase 1 inhibitor PF-04965842, to evaluate the efficacy and safety of PF-04965842 for the treatment of moderate-to-severe atopic dermatitis .
LONDON, UK / ACCESSWIRE / December 14, 2017 / Active-Investors issued a free report on Myriad Genetics, Inc. (NASDAQ: MYGN ) ("Myriad"), which is readily accessible upon registration at www.active-investors.com/registration-sg/?symbol=MYGN ...
The U.S. Food and Drug Administration approved Pfizer Inc's second biosimilar to Johnson & Johnson's blockbuster rheumatoid arthritis drug, Remicade, the company said on Wednesday. Pfizer's Ixifi was approved for all eligible indications of Remicade, including the treatment of bowel disease Crohn's disease and skin disorder plaque psoriasis, the drugmaker said. With the approval, Ixifi joins the ranks of other biosimilars that have claimed market share from Remicade, including Pfizer and Celltrion Inc's Inflectra launched in late 2016, and Renflexis, made by Merck & Co and South Korea's Samsung Bioepis Co Ltd.
Pfizer Inc. today announced that detailed results from two pivotal Phase 3 studies of TRUMENBA® were published in the New England Journal of Medicine .
Cellectis popped early Wednesday after it and Dow's Pfizer presented strong data for first in-human trials of a cancer therapy.
Cellectis saw its shares make a handy gain early on Wednesday after the firm announced preliminary data from its two Phase 1 studies in conjunction with Pfizer.
The Republican-inspired U.S. tax reform could spur an acquisition bonanza in biotech next year. Here's a look at five companies that might be prime targets.
Pfizer Inc. announced today that the U.S. Food and Drug Administration has extended the action date by three months for the supplemental New Drug Application for XELJANZ® , an oral treatment under investigation for adult patients with moderately to severely active ulcerative colitis .
Spark Therapeutics (ONCE) plunged 35% as investors were not impressed by the data from a phase I/II study on its Hemophilia A candidate, SPK-8011.